With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Accordingly to a report released in 2016, there will be about 4,292,000 newly diagnosed invasive cancer cases in 2015 in China, corresponding to an average of almost 12,000 new cancer diagnoses each day. It was also estimated that about 2,814,000 Chinese died from cancer in 2015, corresponding to over 7500 cancer deaths on average per day. There are huge unmet medical needs for cancer patients in China.
Heart failure is the ultimate stage of development for most cardiovascular diseases, characterized by high morbidity, repeated hospitalization rate and mortality, which seriously affects patients' quality of life. According to statistics, 37 million people are living with HF globally, and the annual new cases and mortality of approximately are 2 million and 10% respectively. Especially for the heart failure with preserved ejection fraction (HFpEF) which accounts for more than 50% of all heart failure patients , there is no effective treatment at present. Therefore there is a huge unmet clinical need in the cardiovascular area.
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent, representing a spectrum of clinicopathologic diseases. Non-alcoholic steatohepatitis (NASH) is the predominant type of NAFLD that can progress to cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality. The global prevalence of NAFLD in the general population has been estimated to be 25% but varies across the globe. In the United States, the NAFLD prevalence rate is estimated to be 24%.